Riley Bove

Apr 16, 2024 | neurologylive.com | Riley Bove

WATCH TIME: 5 minutes"From what we can gather from our best data, we don't see any major risk or safety signal [with ocrelizumab], whether that's about the pregnancy itself, or about how the babies are doing."The United States prescription information advises for contraception with ocrelizumab (Ocrevus; Genentech) and for 6 months following the latest infusion; however, patients with multiple sclerosis (MS) may have pregnancies during this interval.

Feb 20, 2024 | nature.com | Alice S. Tang |Jacquelyn Roger |Sarah R. Woldemariam |Riley Bove |Nima Aghaeepour |Tomiko Oskotsky | +1 more

AbstractIdentification of Alzheimer’s disease (AD) onset risk can facilitate interventions before irreversible disease progression. We demonstrate that electronic health records from the University of California, San Francisco, followed by knowledge networks (for example, SPOKE) allow for (1) prediction of AD onset and (2) prioritization of biological hypotheses, and (3) contextualization of sex dimorphism.

Jan 1, 2024 | nature.com | Jiwon Oh |Luca Capezzuto |Lito Kriara |Johan van Beek |Corrado Bernasconi |Xavier Montalban | +6 more

AbstractFloodlight Open was a global, open-access, digital-only study designed to understand the drivers and barriers in deployment and use of a smartphone app in a naturalistic setting and broad study population of people with and without multiple sclerosis (MS).